Dona Ferentes
eidetic cartographer
- Joined
- 11 January 2016
- Posts
- 17,483
- Reactions
- 23,956
CU6 - Clarity Pharmaceuticals
- Thread starter System
- Start date
Country Lad
Off into the sunset
- Joined
- 11 July 2005
- Posts
- 1,639
- Reactions
- 1,668
Thanks @Dona Ferentes I am sure @Joe Blow can sort that out. The imposter has no capital and no space in between. Likely someone could register as donaferentes (no capitals, no space) which the system would accept same as my "shadow". Could become confusing.
Dona Ferentes
eidetic cartographer
- Joined
- 11 January 2016
- Posts
- 17,483
- Reactions
- 23,956
$1.68 ...down from $8+ only six months ago
Clarity receives $11.1 million R&D Tax Incentive refund.
Over $100 million in funding and refocus on high-priority programs.
HIGHLIGHTS
• Clarity received an $11,146,204 Research and Development Tax Incentive refund, inclusive of interest, as part of the Australian Federal Government’s R &D Tax Incentive program.
• The receipt of the $11.1 million will provide additional funding to further the development of Clarity’s Targeted Copper Theranostic platform of products for various cancer indications .
• Clarity is well funded with approximately $106 million in cash, the majority of which will be spent directly on research, development and commercialisation endeavours in the Company’s key programs .
• Following a thorough review of Clarity’s portfolio of clinical-stage assets as well as an in-depth analysis of the markets and their potential risks, the Company will prioritise the development of 64/67Cu-SAR-bisPSMA for both diagnostic and therapeutic applications in prostate cancer as well as the development of 64Cu-SARTATE in neuroendocrine tumours (NETs) and 64Cu-SAR-Bombesin in breast and prostate cancers.
• Clarity will also continue to progress its Discovery Program, aiming to bring key asets such as 64Cu-SAR -bisFAP and 64/67Cu-SAR -trastuzumab to the clinic.
• As part of this priortitisation process, the CL04 trial with 64/67Cu-SARTATE in paediatric high-risk neuroblastoma and the COMBAT trial with 64/67Cu-SAR -Bombesin in low prostate-specific membrane antigen (PSMA) metastatic castration-resistant prostate cancer (mCR P C) will be closed.
Clarity receives $11.1 million R&D Tax Incentive refund.
Over $100 million in funding and refocus on high-priority programs.
HIGHLIGHTS
• Clarity received an $11,146,204 Research and Development Tax Incentive refund, inclusive of interest, as part of the Australian Federal Government’s R &D Tax Incentive program.
• The receipt of the $11.1 million will provide additional funding to further the development of Clarity’s Targeted Copper Theranostic platform of products for various cancer indications .
• Clarity is well funded with approximately $106 million in cash, the majority of which will be spent directly on research, development and commercialisation endeavours in the Company’s key programs .
• Following a thorough review of Clarity’s portfolio of clinical-stage assets as well as an in-depth analysis of the markets and their potential risks, the Company will prioritise the development of 64/67Cu-SAR-bisPSMA for both diagnostic and therapeutic applications in prostate cancer as well as the development of 64Cu-SARTATE in neuroendocrine tumours (NETs) and 64Cu-SAR-Bombesin in breast and prostate cancers.
• Clarity will also continue to progress its Discovery Program, aiming to bring key asets such as 64Cu-SAR -bisFAP and 64/67Cu-SAR -trastuzumab to the clinic.
• As part of this priortitisation process, the CL04 trial with 64/67Cu-SARTATE in paediatric high-risk neuroblastoma and the COMBAT trial with 64/67Cu-SAR -Bombesin in low prostate-specific membrane antigen (PSMA) metastatic castration-resistant prostate cancer (mCR P C) will be closed.
Dona Ferentes
eidetic cartographer
- Joined
- 11 January 2016
- Posts
- 17,483
- Reactions
- 23,956
but closed at $1.90..
Clarity signs high-volume commercial-scale copper-64 Supply Agreement
Highlights
• Clarity has signed a commercial-scale agreement with Nusano, Inc. for supply of copper-64 (Cu-64 or 64Cu) isotope.
• The 190,000 square foot Nusano facility in West Valley City, Utah is capable of producing more than 1,000 Ci (37,000 GBq) of copper-64 per day at capacity, which translates into more than 18,000 patient doses per day at 200 MBq per dose, with a 48-hour shelf-life, far in excess of commercial scale demands across multiple large indications.
• The copper-64 supply from Nusano will complement Clarity’s existing network of US-based suppliers to ensure seamless, abundant production of this diagnostic isotope as the Company is progressing a number of late-stage clinical trials and fast approaching commercialisation.
• Nusano plans to begin production of other medical isotopes, such as copper-67 and actinium-225, both of which are used in Clarity’s products, in 2025-2026.
